
CLAIMS

What is claimed is:

1. A compound wherein the compound has the structure of Formula I




Formula I ,

or a pharmaceutically acceptable salt or prodrug thereof,

wherein R^A is $-CO_2H$, $-CO_2R^B$, -CN, tetrazolyl, $-C(=O)NH_2$, $-C(=O)NHR^B$, $-C(=O)NHSO_2R^B$ or $-C(=O)NHCH_2CH_2SO_3H$ or a carboxylic acid isostere;

wherein R^B is -H or $-C_1$-C_4 alkyl, or has the structure of one of:


;

L^1 is absent or substituted or unsubstituted C_1-C_6 alkylene, substituted or unsubstituted C_3-C_6 cycloalkylene, substituted or unsubstituted C_1-C_6 fluoroalkylene, substituted or unsubstituted C_1-C_6 heteroalkylene, or -UV-Z-, wherein -UV- is defined by -OW-, -WO-, $-N(R^J)W-$, $-WN(R^J)-$, $-N(R^J)C(=O)-$, -SW-, $-S(=O)_nW-$ or $-C(=O)N(R^J)-$,


wherein W is substituted or unsubstituted C_1-C_3 alkylene or substituted or unsubstituted C_3-C_6 cycloalkylene or W is $-C(R^L)_2-$, and

wherein Z is substituted or unsubstituted C_1-C_6 alkylene, substituted or unsubstituted C_3-C_6 cycloalkylene, or C_1-C_6 fluoroalkylene or Z is $-C(R^L)_2-$;

wherein n is 0, 1, or 2;

L^2 is absent, or substituted or unsubstituted C_1-C_6 alkylene, substituted or unsubstituted C_3-C_6 cycloalkylene, substituted or unsubstituted C_1-C_6 fluoroalkylene, substituted or unsubstituted C_1-C_6 heteroalkylene, -O-, -S-, -S(=O)-, $-S(=O)_2-$, $-N(R^J)-$, -C(=O)-, or $-C(=O)N(R^J)-$;

Ring A is a 5 or 6 membered heteroarene selected from one of:



wherein the dashed line indicates the point of attachment of Ring A to Ring B;

wherein one of R^C and R^D is -H, -CN, -F, -Cl, -Br, -I, -OC_1-C_4 alkyl, C_1-C_4 alkyl, C_3-C_6 cycloalkyl, or C_1-C_4 fluoroalkyl,

and the other R^C or R^D is -$N(R^F)$-C(=O)$XCH(R^G)$-CY, -$N(R^F)C(=O)XC(R^G)_2$-CY, -$N(R^F)C(=O)X$-CY, -C(=O)$N(R^F)CH(R^G)X$-CY, or -C(=O)-$N(R^F)C(R^G)_2X$-CY , wherein X is absent, -O-, -NH- or -CH_2-;

R^E is -H, -C_1-C_4 alkyl or -C_1-C_4 fluoroalkyl;

R^F is -H or C_1-C_4 alkyl;

R^G is independently selected R^E, or one R^G is C_1-C_4 alkyl and is taken together with CY and the carbon atom to which R^G and CY are attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, and the other R^G, if present, is as defined for R^E;

CY is substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_3-C_{10} cycloalkyl, substituted or unsubstituted C_2-C_{10} heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 independently selected R^H;

wherein each R^H is independently selected from -H, halogen, -CN, -NO_2, -OH, -OR^J, -SR^J, -S(=O)R^J, -$S(=O)_2R^J$, -$N(R^J)S(=O)_2R^J$, -$S(=O)_2N(R^L)_2$, -C(=O)R^J, OC(=O)R^J, -C(=O)OR^J, -OC(=O)OR^J, -$N(R^L)_2$, -C(=O)$N(R^L)_2$, -OC(=O)$N(R^L)_2$, -$N(R^J)C(=O)N(R^L)_2$, -$N(R^J)C(=O)R^J$, -$N(R^J)C(=O)OR^J$, C_1-C_4 alkyl, C_1-C_4 fluoroalkyl, C_1-C_4 fluoroalkoxy, C_1-C_4 alkoxy, and C_1-C_4 heteroalkyl,

wherein each R^J is independently substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_1-C_6 heteroalkyl, substituted or unsubstituted C_1-C_6 fluoroalkyl, substituted or unsubstituted C_3-C_6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C_1-C_4 alkylene-(substituted or unsubstituted C_3-C_6 cycloalkyl), -C_1-C_4

alkylene-(substituted or unsubstituted heterocycloalkyl), -C_1-C_4 alkylene-(substituted or unsubstituted aryl), or -C_1-C_4 alkylene-(substituted or unsubstituted heteroaryl);

wherein each R^L is independently -H, substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_1-C_6 heteroalkyl, substituted or unsubstituted C_1-C_6 fluoroalkyl, substituted or unsubstituted C_3-C_6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C_1-C_4 alkylene-(substituted or unsubstituted cycloalkyl), -C_1-C_4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C_1-C_4 alkylene(substituted or unsubstituted aryl), or -C_1-C_4 alkylene-(substituted or unsubstituted heteroaryl),

or when R^H is -$S(=O)_2N(R^L)_2$, -$N(R^L)_2$, -$C(=O)N(R^L)_2$, -$OC(=O)N(R^L)_2$ or $N(R^J)C(=O)N(R^L)_2$, each R^L is independently -H or C_1-C_6 alkyl, or the R^L groups independently are C_1-C_6 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle,

or when W is -$C(R^L)_2$- or Z is -$C(R^L)_2$-, each R^L is independently -H or C_1-C_6 alkyl, or the R^L groups independently are C_1-C_6 alkyl which are taken together with the carbon atom to which they are attached to define a carbocycle;

Ring B is substituted or unsubstituted C_3-C_{10} cycloalkylene, substituted or unsubstituted C_2-C_{10} heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, where if ring B is substituted then ring B is substituted with 1, 2, or 3 independently selected R^H, wherein R^H is as previously defined;


Ring C is absent or substituted or unsubstituted C_3-C_{10} cycloalkylene, substituted or unsubstituted C_2-C_{10} heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, where if ring C is substituted then ring C is substituted with 1, 2, or 3 independently selected R^H, wherein R^H is as previously defined,

wherein when Ring B is substituted or unsubstituted arylene, Ring C is absent, L^2 is absent, L^1 is -UV-Z-, wherein -UV- is -$N(R^F)$-$C(=O)O$-, wherein R^F is -H, R^D is -$N(R^F)C(=O)XCH(R^G)$-CY, wherein X is -O-, R^G is -CH_3 and R^F is -H, and R^C is -H, -CH_3 or -CF_3,

or when Ring B is substituted or unsubstituted arylene and Ring C is substituted or unsubstituted arylene or is substituted or unsubstituted C_3-C_{10} cycloalkylene, or Ring B is substituted or unsubstituted C_3-C_{10} cycloalkylene and Ring C is substituted or unsubstituted arylene, L^2 is absent and L^1 is C_1-C_6 alkylene,


and R^C is -H or -CH_3 and R^A is -CO_2H or CO_2R^B,

then Ring A has the structure of one of::




and when Ring B is C_2-C_{10} heterocycloalkylene, Ring C is substituted or unsubstituted arylene, L^2 is absent, L^1 is C_1-C_6 alkylene, R^C is $-CH_3$ and R^A is $-CO_2H$ or CO_2R^B,

then Ring A has the structure of one of:



2. The compound of claim 1 wherein R^C is -H, -CN, -F, -Cl, -Br, -I, $-OC_1$-C_4 alkyl, $-C_1$-C_4 alkyl, $-C_3$-C_6 cycloalkyl, or $-C_1$-C_4 fluoroalkyl and R^D is $-N(R^F)$-$C(=O)XCH(R^G)$-CY, $-N(R^F)C(=O)XC(R^G)_2$-CY, $-N(R^F)C(=O)X$-CY, wherein R^F and each R^G independently are -H or C_1-C_4 alkyl.

3. The compound of claim 2 wherein Ring A is selected from one of:



;


R^D is $-N(R^F)C(=O)XCH(R^G)-CY$, and R^C is -H, $-CH_3$ or $-CF_3$,

Ring B is substituted or unsubstituted arylene or substituted or unsubstituted heteroarylene; and

Ring C is absent; L^2 is absent; L^1 is -UV-Z-, wherein -UV- is -OW-, -WO-, $-N(R^J)W-$, $-WN(R^J)-$, $-N(R^J)C(=O)-$, -SW-, $-S(=O)_nW-$, or $-C(=O)N(R^J)-$, wherein W is substituted or unsubstituted C_1-C_3 alkylene; and n is 0, 1, or 2;

or Ring B and Ring C independently are substituted or unsubstituted arylene or substituted or unsubstituted arylene, L^2 is absent and L^1 is C_1-C_6 alkylene.

4. The compound of claim 2 wherein Ring A has the structure of one of:



;

wherein Ring B is substituted or unsubstituted arylene and Ring C is substituted or unsubstituted arylene or is substituted or unsubstituted C_3-C_{10} cycloalkylene,

or Ring B is substituted or unsubstituted C_3-C_{10} cycloalkylene and Ring C is substituted or unsubstituted arylene, L^2 is absent and L^1 is C_1-C_6 alkylene.

5. The compound of claim 2 wherein

L^2 is absent and L^1 is C_1-C_6 alkylene, substituted or unsubstituted C_3-C_6 cycloalkylene, or substituted or unsubstituted C_1-C_6 heteroalkylene

or L^2 and Ring C are absent and L^1 is -UV-Z-, wherein -UV- is defined by -OW-, -WO-, -N(R^J)W-, -WN(R^J)-, -N(R^J)C(=O)-, -SW-, -S(=O)$_n$W-, or -C(=O)N(R^J)-, wherein W is substituted or unsubstituted C_1-C_3 alkylene; and n is 0, 1, or 2.

6. The compound of claim 5 wherein L^1 is -UV-Z- wherein -UV- is defined by -OW-, -WO-, -N(R^J)W-, -WN(R^J)- or -C(=O)N(R^J)-, wherein W is substituted or unsubstituted C_1-C_3 alkylene.

7. The compound of claim 5 wherein L^1 is -UV-Z-, wherein -UV- is defined by -WO-, -WN(R^J)- or -C(=O)N(R^J)-, wherein W is substituted or unsubstituted C_1-C_3 alkylene, and L^2 is absent.

8. The compound of claim 7 wherein Z is substituted or unsubstituted C_1-C_6 alkylene.

9. The compound of claim 7 wherein Z is substituted or unsubstituted C_1-C_6 alkylene and R^A is -CO_2H or -CO_2R^B.

10. The compound of claim 7, wherein L^1 is -UV-Z-, wherein -UV- is defined by -C(=O)N(R^J)-, wherein R^J is -H or -CH_3.


11. The compound of claim 7 wherein L^1 is UV-Z-, wherein -UV-, is defined by -WO-.

12. The compound of claim 7 wherein L^1 is UV-Z-, wherein -UV- is defined by - WN(R^J)-, wherein R^J is -H or -CH_3.

13. The compound of claim 2 wherein L^1 is absent or a substituted or unsubstituted substituted C_1-C_4 alkylene or a substituted or unsubstituted C_3 cycloalkylene (i.e., cyclopropyl-di-yl).

14. The compound of claim 2 wherein L^1 is -CH_2-,  or -$C(CH_3)_2$-.

15. The compound of claim 2 wherein Ring A has the structure of one of:



,

wherein R^C is -H, -CN, $-CH_3$, -F or $-CF_3$, R^D is $-N(R^F)C(=O)XCH(R^G)$-CY, $-N(R^F)C(=O)XC(R^G)_2$-CY, or $-N(R^F)C(=O)X$-CY and L^1 is -UV-Z- wherein -UV- is defined by -WO -, $-WN(R^J)$- or $-C(=O)N(R^J)$-.

16. The compound of claim 15 wherein R^C is -H, $-CH_3$, -F or $-CF_3$ and R^D is $-N(R^F)C(=O)XCH(R^G)$-CY.

17. The compound of claim 15 wherein R^D is $-N(R^F)C(=O)XCH(R^G)$-CY, wherein -X- is $-N(R^F)$- or -O-; and wherein R^G and each R^F, independently selected, are -H or $-CH_3$.

18. The compound of claim 17 wherein R^G is $-CH_3$, in the *R* or *S* configuration, and CY is substituted or unsubstituted phenyl or substituted or unsubstituted heteroaryl.

19. The compound of claim 17 wherein R^D is $-N(R^F)C(=O)OCH(R^G)$-CY, wherein CY is substituted or unsubstituted phenyl, wherein substituted phenyl is phenyl that is substituted with one or two of independently selected R^J.


20. The compound of claim 17 wherein R^D is $-N(R^F)C(=O)OCH(CH_3)$-CY, wherein R^F is -H, and wherein CY is unsubstituted phenyl.

21. The compound of claim 17 wherein R^D is $-N(R^F)$-$C(=O)OCH(CH_3)$-CY, wherein R^F is -H, and wherein CY is substituted phenyl, wherein substituted phenyl is phenyl that is substituted with one or two of independently selected R^J, wherein R^J are halogens.

22. The compound of claim 21 wherein R^D is -NH-$C(=O)OCH(CH_3)$-CY wherein CY is substituted phenyl, wherein substituted phenyl is phenyl that is substituted with one R^J, wherein R^J is -F, -Cl or -Br.

23. The compound of claim 21 wherein R^D is -NH-C(=O)OCH(CH_3)-CY, wherein CY is substituted phenyl, wherein substituted phenyl is phenyl that is substituted with one R^J, wherein R^J is -Cl.


24. The compound of claim 19 wherein R^D is -NHC(=O)OCH(CH_3)-CY having the structure of



.

25. The compound of claim 19 wherein R^D is -NHC(=O)OCH(CH_3)-CY wherein the methyl group in R^D is in the *R* configuration.

26. The compound of any one of claims 5-25 wherein Ring A has the structure of:



,

wherein L^2 is absent and Ring B is substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, provided that when

Ring C is not absent and L^1 is C_1-C_6 alkylene, or Ring C is absent and L^1 is -UV-Z, wherein -UV- is -N(R^F)-C(=O)O-,

and R^D has the structure of -N(R^F)-C(=O)XCH(R^G)-CY, -N(R^F)-C(=O)XC(R^G)$_2$-CY or -N(R^F)-C(=O)X-CY,

and R^A is -CO_2H or CO_2R^B,

then R^C is other than -H, -CH_3 and -CF_3.

27. The compound of claim 26 wherein R^C is -H, -CH_3 or -CF_3, and R^D is -NH-C(=O)OCH(R^G)-CY, wherein R^G is -H or -CH_3, in the *R* or *S* configuration, and -CY is substituted or unsubstituted phenyl.

28. The compound of claim 26 wherein L^2 and Ring C are absent, Ring B is substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, and L^1 is -UV-Z-, wherein -UV-, is defined by -WO-, -WN(R^J)- or -C(=O)N(R^J)-.

29. The compound of claim 26 wherein L^2 and Ring C are absent, Ring B is substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, and L^1 is -UV-Z-, wherein -UV-, is defined by $-WN(R^J)-$ or $-C(=O)N(R^J)-$, wherein R^J is -H or $-CH_3$.

30. The compound of claim 29 wherein L^1 is -UV-Z-, wherein -UV- is defined by -C(=O)NH-, and wherein Z is substituted or unsubstituted C_1-C_6 alkylene.

31. The compound of claim 29 wherein L^1 is -UV-Z-, wherein -UV- is defined by -WO-, wherein W is substituted or unsubstituted C_1-C_3 alkylene, and wherein Z is substituted or unsubstituted C_1-C_6 alkylene.

32. The compound of claim 29 wherein L^1 is -UV-Z-, wherein -UV- is defined by -W-NH-, wherein W is substituted or unsubstituted C_1-C_3 alkylene, and wherein Z is substituted or unsubstituted C_1-C_6 alkylene.


33. The compound of claim 26 wherein L^1 is -UV-Z-, wherein -UV- is defined by -WO-, $-WN(R^J)-$ or $-C(=O)N(R^J)$, wherein R^J is -H or $-CH_3$, and wherein Z is substituted or unsubstituted C_1-C_6 alkylene, wherein the alkylene is $-CH(CH_2\text{-cyclopropyl})-$, $-CH(CH_2\text{-aryl})$ or $-CH(CH_2\text{-heteroaryl})$, wherein the aryl or heteroaryl is substituted or unsubstituted.

34. The compound of claim 33 wherein L^1 is -UV-Z-, wherein -UV- is defined by -C(=O)NH-, -WO- or -W-NH-, wherein -W- is $-CH_2-$; and R^A is $-CO_2H$ or $-CO_2R^B$.


35. The compound of claim 33 wherein L^1 is -UV-Z-, wherein -UV- is defined by $-CH_2O-$, $-CH_2$-NH- or -C(=O)NH-, wherein Z is substituted or unsubstituted C_1-C_6 alkylene, wherein the alkylene is $-CH(CH_2\text{-cyclopropyl})-$, $-CH(CH_2\text{-aryl})$ or $-CH(CH_2\text{-heteroaryl})$, wherein the aryl or heteroaryl is unsubstituted or substituted with 1, 2, or 3 independently selected substituted or unsubstituted C_1-C_4 alkyl or halogen.

36. The compound of claim 35 wherein said substituted or unsubstituted C_1-C_4 alkyl or halogen substituent or substituents of the aryl or heteroaryl of $-CH(CH_2\text{-aryl})$ or $-CH(CH_2\text{-heteroaryl})$ are selected from the group consisting of $-CH_3$, $-CF_3$, -F, -Cl and -Br.


37. The compound of claim 33, wherein L^1 is -UV-Z- and wherein R^A is $-CO_2H$ to which Z is attached to define $-L^1-R^A$ (i.e., $-UV-Z-R^A$), wherein -UV- is defined by -C(=O)NH-, -WO- or -W-NH-, wherein -W- is $-CH_2-$, and Z is $-CH(CH_2\text{-aryl})$, wherein the aryl is substituted or unsubstituted, having the structure of one of:



[H, Cl]



[H, F, Cl, CH_3, CF_3]





[H, F]


[H, F, Cl, Br, CH_3, CF_3]

38. The compound of claim 37 wherein the $-CH(CH_2\text{-aryl})$ substituent of Z in $-L^1-R^A$ is in the *R* configuration.


39. The compound of claim 33 wherein L^1 is -UV-Z- and wherein R^A is $-CO_2H$ to which Z is attached to define $-L^1-R^A$ (i.e., $-UV-Z-R^A$), wherein -UV- is defined by -C(=O)NH-, -WO- or -W-NH-, wherein -W- is $-CH_2-$, and Z is $-CH(CH_2\text{-cyclopropyl})-$, having the structure of







40. The compound of claim 1, 2, 3, or 4, wherein the compound has the structure of Formula V




Formula V


,

wherein A^1, A^2 and A^3 are independently -N=, =N-, =CH- or -CH=.


41. The compound of claim 40 wherein Ring A wherein Ring A has the structure of one of:



wherein when L^1 is C_1-C_6 alkylene, R^D is $-N(R^F)C(=O)XCH(R^G)$-CY, $-N(R^F)C(=O)XC(R^G)_2$-CY, wherein R^F is -H, R^G is -H or $-CH_3$; R^A is $-CO_2H$ or $-CO_2R^B$, and R^C is -H or $-CH_3$, then Ring A has the structure of one of:




42. The compound of claim 40,wherein Ring A has the structure of one of:




wherein Ring C is a substituted or unsubstituted arylene or heteroarylene, L^1 is C_1-C_6 alkylene, R^A is $-CO_2H$ or $-CO_2R^B$, R^D is $-N(R^F)C(=O)XCH(R^G)$-CY, $-N(R^F)C(=O)XC(R^G)_2$-CY, wherein R^F is -H, R^G is $-CH_3$ and CY is substituted phenyl and R^C is - is -CN, -F, -Cl, -Br, -I, $-OC_1$-C_4 alkyl, C_2-C_4 alkyl, C_3-C_6 cycloalkyl, or C_2-C_4 fluoroalkyl.

43. The compound of claim 40, wherein Ring A has the structure of one of:



wherein Ring C is a substituted or unsubstituted arylene or heteroarylene, L^1 is C_1-C_6 alkylene, R^A is $-CO_2H$ or $-CO_2R^B$, R^D is $-N(R^F)C(=O)XCH(R^G)$-CY, $-N(R^F)C(=O)XC(R^G)_2$-CY, wherein X is -O-, R^F is $-CH_3$, R^G is -H or $-CH_3$ and CY is substituted phenyl; and R^C is - is -H, -CN, -F, -Cl, -Br, -I, $-OC_1$-C_4 alkyl, C_1-C_4 alkyl, C_3-C_6 cycloalkyl, or C_1-C_4 fluoroalkyl.


44. The compound of claim 1, 2 or 5 wherein the compound has the structure of Formula IV



Formula IV

,

wherein Ring A has the structure of one of:



,

wherein A^1 is =N- or =C-;


R^D is $-NR^FC(=O)OCH(R^G)$-CY.

L^1 is -UV-Z-, wherein -UV- is defined by $-C(=O)N(R^J)$-, wherein R^J is -H or $-CH_3$;

R^F and R^G independently are -H or $-CH_3$; and

R^A is $-CO_2H$ or $-CO_2R^B$.


45. The compound of claim 2 wherein the compound has the structure of Formula VII



Formula VI

,

wherein Ring A is a 5 membered heteroarene having one of the structures of:



,


wherein R^D is the $-N(R^F)C(=O)CH(R^G)$-CY substituent of Formula VI wherein CY is phenyl substituted with one R^H, and R^C is -H, $-CH_3$, CF_3 or -F.

R^A is $-CO_2H$ or $-CO_2R^B$; and

R^F and R^G independently are -H or $-CH_3$; and

R^H independently are -H, halogen, $-CH_3$ or $-CF_3$.

46. The compound of claim 2 wherein the compound has the structure of Formula VII




Formula VII

,

wherein A^1 is =CH- or =N-;

Ring A is a 5 membered heteroarene having the structure of one of:



,

wherein R^D is the -N(R^F)C(=O)CH(R^G)-CY substituent of Formula VII wherein CY is phenyl substituted with one R^H; and R^C is -H, $-CH_3$, $-CF_3$ or -F;

R^A is $-CO_2H$ or $-CO_2R^B$;


R^E and R^F independently are -H or C_1-C_4 alkyl;

R^G is -H or $-CH_3$;

R^H is -H, halogen, $-CH_3$ or $-CF_3$; and

Z is $-C(R^L)_2$, wherein one R^L is -H and the other R^L is -H or C_1-C_4 alkyl.

47. The compound of claim 2 wherein the compound has the structure of Formula VIII




Formula VIII

,

wherein A^1 is =CH- or =N-;

wherein Ring A is a 5 membered heteroarene having the structure of one of:



,

wherein R^D is the -N(R^F)C(=O)CH(R^G)-CY substituent of Formula VIII wherein CY is phenyl substituted with one R^H;

R^A is -CO_2H or -CO_2R^B;

W is -C(R^L)$_2$- or  ;


R^E and R^F independently are -H or C_1-C_4 alkyl;

R^G is -H or -CH_3;

R^H is -H, halogen, -CH_3 or -CF_3; and

Z is -C(R^L)$_2$, wherein one R^L is -H and the other R^L is -H or C_1-C_4 alkyl.

48. The compound of claim 2 wherein the compound has the structure of Formula IX




Formula IX

,

wherein A^1 is =CH- or =N-;

wherein Ring A is a 5 membered heteroarene having the structure of one of:



,

wherein R^D is the -N(R^F)C(=O)CH(R^G)-CY substituent of Formula VII wherein CY is phenyl substituted with one R^H;

R^A is -CO_2H or -CO_2R^B;

wherein W is -C(R^L)$_2$- or  ;


R^E and R^F independently are -H or C_1-C_4 alkyl;

R^G is -H or -CH_3;

R^H is -H, halogen, -CH_3 or -CF_3; and

Z is -C(R^L)$_2$, wherein one R^L is -H and the other R^L is -H or C_1-C_4 alkyl.


49. The compound of claim 2 wherein the compound has the structure of Formula XII



Formula XII

wherein A^1 is =CH- or =N-;

wherein Ring A is a 5 membered heteroarene having the structure of one of



,

wherein R^D is the -N(R^F)C(=O)CH(R^G)-CY substituent of Formula VII wherein CY is phenyl substituted with one R^H;

R^A is -CO_2H or -CO_2R^B;

wherein W is $-C(R^L)_2-$ or  ;

R^E and R^F independently are -H or C_1-C_4 alkyl;

R^G is -H or $-CH_3$;

R^H is -H, halogen, $-CH_3$ or $-CF_3$; and

Z is $-C(R^L)_2$, wherein one R^L is -H and the other R^L is -H or C_1-C_4 alkyl.

50. The compound of claim 2 wherein the compound is selected from Table 1.

51. The compound of claim 50 wherein the compound is 1-(4-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-cyclopropanecarboxylic acid, 2-(4-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-indan-2-carboxylic acid, 2-(S)-(4-{4-[(R,S)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino) phenyl acetic acid, 2-(R)-(4-{4-[(R,S)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino) phenyl propanoic acid, 2(R)-[[4-[3-methyl-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid, 2(S)-[[4-[3-methyl-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid, (*R*)-2-[[4-[2,5-dimethyl-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-phenyl-propanoic acid, (R)-2-[[4-[1,5-dimethyl-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-phenyl-propanoic acid, (R)-2-[[4-[2,5-dimethyl-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid, (R)-2-[[4-[1,5-dimethyl-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid, (R)- 3-(4-bromophenyl)-2-[[4-[2,5-dimethyl-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, (R)- 3-(4-bromophenyl)-2-[[4-[1,5-dimethyl-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, (R)- 3-(4-chlorophenyl)-2-[[4-[2,5-dimethyl-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, (R)- 3-(4-chlorophenyl)-2-[[4-[1,5-dimethyl-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, (R)- 3-(3,4-difluorophenyl)-2-[[4-[2,5-dimethyl-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, (R)- 3-(3,4-difluorophenyl)-2-[[4-[1,5-dimethyl-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, (R)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-cyclopropyl-propionic acid, (R)-2-{4-[3-Methyl-4-((S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzoylamino}-3-phenyl-propionic acid, (S)-2-{4-[3-Methyl-4-((S)-1-phenyl-

ethoxycarbonylamino)-isoxazol-5-yl]-benzoylamino}-3-phenyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-phenyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-(4-fluoro-phenyl)-propionic acid, (R)-3-(4-Chloro-phenyl)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-(3,4-difluoro-phenyl)-propionic acid, (R)-3-(2-Chloro-phenyl)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-propionic acid, (R)-3-(4-Bromo-phenyl)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-propionic acid, (R)-3-(4-Bromo-phenyl)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-(2-fluoro-phenyl)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-p-tolyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-(4-trifluoromethyl-phenyl)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-(4-cyano-phenyl)-propionic acid, (R)- 2-(4-{5-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-methyl-pyrazol-1-yl}-benzoylamino)-3-phenyl-propionic acid, (R)-2-{4-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzylamino}-3-phenyl-propionic acid, (R)-3-(2-Fluoro-phenyl)-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzylamino}-propionic acid, (R)-2-{4-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzylamino}-3-(4-trifluoromethyl-phenyl)-propionic acid, (R)-3-Cyclopropyl-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzylamino}-propionic acid, (R)-3-(2-Chloro-phenyl)-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzylamino}-propionic acid, (R)-3-(4-Chloro-phenyl)-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzylamino}-propionic acid, (R)- 2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzylamino)-3-phenyl-propionic acid, (R)- 2-(4-{4-[(R)_1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzylamino)-3-(2-fluoro-phenyl)-propionic acid, (R)- 2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzylamino)-3-(4-trifluoromethyl-phenyl)-propionic acid, (R)- 3-(2-Chloro-phenyl)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzylamino)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzylamino)-3-cyclopropyl-propionic acid, 2-{4-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-

isoxazol-5-yl]-benzyloxy}-3-phenyl-propionic acid, (RS)-3-Cyclopropyl-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid, (RS)-3-Cyclopropyl-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid, 2-[4-[4-[5-[1-(2-chlorophenyl)ethoxycarbonylamino]-4-cyano-pyrazol-1-yl]phenyl]phenyl]acetic acid, (R)-1-[4-[4-[1,5-dimethyl-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]phenyl]phenyl]cyclopropane carboxylic acid, (R)-1-[4-[4-[2,5-dimethyl-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]phenyl]phenyl]cyclopropane carboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-3-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(2-Chloro-4'-{5-[1-(2-chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-methyl-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid, (R)- 1-{4'-[5-(1-Phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, (R)-1-{2-Fluoro-4'-[5-(1-phenyl-ethoxycarbonylamino)-4-trifluoromethyl-pyrazol-1-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid, (R)-1-(4-{5-[5-(1-Phenyl-ethoxycarbonylamino)-pyrazol-1-yl]-pyridin-2-yl}-phenyl)-cyclopropanecarboxylic acid.


52. The compound of claim 50 wherein the compound is (RS)-3-Cyclopropyl-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4'-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid

53. A compound of any one of claims 1-52 for preparation of mendicant for treating a LPA-dependent disease or condition.

CLAIMS

What is claimed is:


1. A compound wherein the compound has the structure of Formula I



Formula I

or a pharmaceutically acceptable salt or prodrug thereof, wherein

Ring A is a 5 or 6 membered heteroarene selected from one of:



wherein the dashed line indicates the point of attachment of Ring A to Ring B;

Ring B is substituted or unsubstituted C_3-C_{10} cycloalkylene, substituted or unsubstituted C_2-C_{10} heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene, where if ring B is substituted then ring B is substituted with 1, 2, or 3 independently selected R^H;

Ring C is absent;

L^1 is -UV-Z-;

UV is -OW-, -WO-, -N(R^J)W-, -WN(R^J)- or -C(=O)N(R^J)-, wherein W is substituted or unsubstituted C_1-C_3 alkylene;


W is substituted or unsubstituted C_1-C_3 alkylene or substituted or unsubstituted C_3-C_6 cycloalkylene, or W is -C(R^L)$_2$-;

Z is substituted or unsubstituted C_1-C_6 alkylene, substituted or unsubstituted C_3-C_6 cycloalkylene, or C_1-C_6 fluoroalkylene or Z is -C(R^L)$_2$-;

L^2 is absent;

R^A is -CO_2H, -CO_2R^B, -CN, tetrazolyl, -C(=O)NH_2, -C(=O)NHR^B, -C(=O)NHSO_2R^B or -C(=O)N$HCH_2CH_2SO_3$H or a carboxylic acid isostere;

R^B is -H or -C_1-C_4 alkyl, or has the structure of one of:



R^C is -H, -CN, -F, -Cl, -Br, -I, -OC_1-C_4 alkyl, -C_1-C_4 alkyl, -C_3-C_6 cycloalkyl, or -C_1-C_4 fluoroalkyl;

R^D is -$N(R^F)$-C(=O)$XCH(R^G)$-CY, -$N(R^F)$C(=O)$XC(R^G)_2$-CY, -$N(R^F)$C(=O)X-CY, wherein R^F and each R^G independently are -H or C_1-C_4 alkyl.

R^E is -H, -C_1-C_4 alkyl or -C_1-C_4 fluoroalkyl;

R^F is -H or C_1-C_4 alkyl;

R^G is independently selected R^E, or one R^G is C_1-C_4 alkyl and is taken together with CY and the carbon atom to which R^G and CY are attached to define a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, and the other R^G, if present, is as defined for R^E;

CY is substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_3-C_{10} cycloalkyl, substituted or unsubstituted C_2-C_{10} heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 independently selected R^H;

wherein each R^H is independently selected from -H, halogen, -CN, -NO_2, -OH, -OR^J, -SR^J, -S(=O)R^J, -$S(=O)_2R^J$, -$N(R^J)S(=O)_2R^J$, -$S(=O)_2N(R^L)_2$, -C(=O)R^J, OC(=O)R^J, -C(=O)OR^J, -OC(=O)OR^J, -$N(R^L)_2$, -C(=O)$N(R^L)_2$, -OC(=O)$N(R^L)_2$, -$N(R^J)C(=O)N(R^L)_2$, -$N(R^J)C(=O)R^J$, -$N(R^J)C(=O)OR^J$, C_1-C_4 alkyl, C_1-C_4 fluoroalkyl, C_1-C_4 fluoroalkoxy, C_1-C_4 alkoxy, and C_1-C_4 heteroalkyl,

wherein each R^J is independently substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_1-C_6 heteroalkyl, substituted or unsubstituted C_1-C_6 fluoroalkyl, substituted or unsubstituted C_3-C_6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C_1-C_4 alkylene-(substituted or unsubstituted C_3-C_6 cycloalkyl), -C_1-C_4 alkylene-(substituted or unsubstituted heterocycloalkyl), -C_1-C_4 alkylene-(substituted or unsubstituted aryl), or -C_1-C_4 alkylene-(substituted or unsubstituted heteroaryl);

wherein each R^L is independently -H, substituted or unsubstituted C_1-C_6 alkyl, substituted or unsubstituted C_1-C_6 heteroalkyl, substituted or unsubstituted C_1-C_6 fluoroalkyl, substituted or unsubstituted C_3-C_6 cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C_1-C_4 alkylene-(substituted or unsubstituted cycloalkyl), -C_1-C_4 alkylene-(substituted or unsubstituted

heterocycloalkyl), -C_1-C_4 alkylene(substituted or unsubstituted aryl), or -C_1-C_4 alkylene-(substituted or unsubstituted heteroaryl),

or when R^H is -$S(=O)_2N(R^L)_2$, -$N(R^L)_2$, -$C(=O)N(R^L)_2$, -$OC(=O)N(R^L)_2$ or $N(R^J)C(=O)N(R^L)_2$, each R^L is independently -H or C_1-C_6 alkyl, or the R^L groups independently are C_1-C_6 alkyl which are taken together with the N atom to which they are attached to define a substituted or unsubstituted heterocycle,

or when W is -$C(R^L)_2$- or Z is -$C(R^L)_2$-, each R^L is independently -H or C_1-C_6 alkyl, or the R^L groups independently are C_1-C_6 alkyl which are taken together with the carbon atom to which they are attached to define a carbocycle;

2. The compound of claim 1 wherein L^1 is -UV-Z- wherein -UV- is defined by -OW-, -WO-, -$N(R^J)$W-, -$WN(R^J)$- or -$C(=O)N(R^J)$-, wherein W is substituted or unsubstituted C_1-C_3 alkylene.

3. The compound of claim 2 wherein Z is substituted or unsubstituted C_1-C_6 alkylene.

4. The compound of claim 2 wherein Z is substituted or unsubstituted C_1-C_6 alkylene and R^A is -CO_2H or -CO_2R^B.

5. The compound of claim 2, wherein L^1 is -UV-Z-, wherein -UV- is defined by -$C(=O)N(R^J)$-, wherein R^J is -H or -CH_3.

6. The compound of claim 2 wherein L^1 is UV-Z-, wherein -UV-, is defined by -WO-.

7. The compound of claim 2 wherein L^1 is UV-Z-, wherein -UV-, is defined by - $WN(R^J)$-, wherein R^J is -H or -CH_3.

8. The compound of claim 1 wherein R^C is -H, -CN, -CH_3, -F or -CF_3, R^D is -$N(R^F)C(=O)XCH(R^G)$-CY, -$N(R^F)C(=O)XC(R^G)_2$-CY, or -$N(R^F)C(=O)X$-CY and L^1 is -UV-Z- wherein -UV- is defined by -WO -, -$WN(R^J)$- or -$C(=O)N(R^J)$-.

9. The compound of claim 8 wherein R^C is -H, -CH_3, -F or -CF_3; and R^D is -$N(R^F)C(=O)XCH(R^G)$-CY.

10. The compound of claim 9 wherein R^D is -N(R^F)C(=O)XCH(R^G)-CY, wherein -X- is -N(R^F)- or -O-; and wherein R^G and each R^F, independently selected, are -H or -CH_3.

11. The compound of claim 10 wherein R^G is -CH_3, in the *R* or *S* configuration, and CY is substituted or unsubstituted phenyl or substituted or unsubstituted heteroaryl.

12. The compound of claim 10 wherein R^D is -N(R^F)C(=O)OCH(R^G)-CY, wherein CY is substituted or unsubstituted phenyl, wherein substituted phenyl is phenyl that is substituted with one or two of independently selected R^J.


13. The compound of claim 10 wherein R^D is -N(R^F)C(=O)OCH(CH_3)-CY, wherein R^F is -H, and wherein CY is unsubstituted phenyl.

14. The compound of claim 10 wherein R^D is -N(R^F)-C(=O)OCH(CH_3)-CY, wherein R^F is -H, and wherein CY is substituted phenyl, wherein substituted phenyl is phenyl that is substituted with one or two of independently selected R^J, wherein R^J are halogens.

15. The compound of claim 14 wherein R^D is -NH-C(=O)OCH(CH_3)-CY wherein CY is substituted phenyl, wherein substituted phenyl is phenyl that is substituted with one R^J, wherein R^J is -F, -Cl or -Br.

16. The compound of claim 14 wherein R^D is -NH-C(=O)OCH(CH_3)-CY, wherein CY is substituted phenyl, wherein substituted phenyl is phenyl that is substituted with one R^J, wherein R^J is -Cl.


17. The compound of claim 14 wherein R^D is -NHC(=O)OCH(CH_3)-CY having the structure of



.

18. The compound of claim 14 wherein R^D is -NHC(=O)OCH(CH_3)-CY wherein the methyl group in R^D is in the *R* configuration.

19. The compound of any one of claims 1-18 wherein Ring A has the structure of:



and Ring B is substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

20. The compound of claim 19 wherein R^C is -H, -CH_3 or -CF_3, and R^D is -NH-C(=O)OCH(R^G)-CY, wherein R^G is -H or -CH_3, in the *R* or *S* configuration, and -CY is substituted or unsubstituted phenyl.

21. The compound of claim 19 wherein L^1 is -UV-Z-, wherein -UV-, is -WO-, -WN(R^J)- or -C(=O)N(R^J)-.

22. The compound of claim 19 wherein L^1 is -UV-Z-, wherein -UV-, is -WN(R^J)- or -C(=O)N(R^J)-, wherein R^J is -H or -CH_3.

23. The compound of claim 22 wherein L^1 is -UV-Z-, wherein -UV- is defined by -C(=O)NH-, and wherein Z is substituted or unsubstituted C_1-C_6 alkylene.

24. The compound of claim 22 wherein L^1 is -UV-Z-, wherein -UV- is defined by -WO-, wherein W is substituted or unsubstituted C_1-C_3 alkylene, and wherein Z is substituted or unsubstituted C_1-C_6 alkylene.

25 The compound of claim 22 wherein L^1 is -UV-Z-, wherein -UV- is defined by -W-NH-, wherein W is substituted or unsubstituted C_1-C_3 alkylene, and wherein Z is substituted or unsubstituted C_1-C_6 alkylene.

26. The compound of claim 22 wherein L^1 is -UV-Z-, wherein -UV- is defined by -WO-, -WN(R^J)- or -C(=O)N(R^J), wherein R^J is -H or -CH_3, and wherein Z is substituted or unsubstituted


C_1-C_6 alkylene, wherein the alkylene is -CH(CH_2-cyclopropyl)-, -CH(CH_2-aryl) or -CH(CH_2-heteroaryl), wherein the aryl or heteroaryl is substituted or unsubstituted.

27. The compound of claim 26 wherein L^1 is -UV-Z-, wherein -UV- is defined by -C(=O)NH-, -WO- or -W-NH-, wherein -W- is -CH_2-; and R^A is -CO_2H or -CO_2R^B.


28. The compound of claim 26 wherein L^1 is -UV-Z-, wherein -UV- is defined by -CH_2O-, -CH_2-NH- or -C(=O)NH-, wherein Z is substituted or unsubstituted C_1-C_6 alkylene, wherein the alkylene is -CH(CH_2-cyclopropyl)-, -CH(CH_2-aryl) or -CH(CH_2-heteroaryl), wherein the aryl or heteroaryl is unsubstituted or substituted with 1, 2, or 3 independently selected substituted or unsubstituted C_1-C_4 alkyl or halogen.

29. The compound of claim 28 wherein said substituted or unsubstituted C_1-C_4 alkyl or halogen substituent or substituents of the aryl or heteroaryl of -CH(CH_2-aryl) or -CH(CH_2-heteroaryl) are selected from the group consisting of -CH_3, -CF_3, -F, -Cl and -Br.


30. The compound of claim 26, wherein L^1 is -UV-Z- and wherein R^A is -CO_2H to which Z is attached to define -L^1-R^A (i.e., -UV-Z-R^A), wherein -UV- is defined by -C(=O)NH-, -WO- or -W-NH-, wherein -W- is -CH_2-, and Z is -CH(CH_2-aryl), wherein the aryl is substituted or unsubstituted, having the structure of one of:



[H, Cl]



[H, F, Cl, CH_3, CF_3]




[H, F]

[H, F, Cl, Br, CH_3, CF_3]


.

31. The compound of claim 30 wherein the -CH(CH_2-aryl) substituent of Z in -L^1-R^A is in the *R* configuration.

32. The compound of claim 26 wherein L^1 is -UV-Z- and wherein R^A is $-CO_2H$ to which Z is attached to define $-L^1-R^A$ (i.e., $-UV-Z-R^A$), wherein -UV- is defined by -C(=O)NH-, -WO- or -W-NH-, wherein -W- is $-CH_2$ -, and Z is $-CH(CH_2$-cyclopropyl)-, having the structure of




33. The compound of claim 1, wherein the compound has the structure of Formula IV



Formula IV

wherein Ring A is a 5-membered heteroarylene having the structure of one of:



wherein A^1 is =N- or =C-;

R^D is $-NR^FC(=O)OCH(R^G)$-CY.


L^1 is -UV-Z-,

UV is $-C(=O)N(R^J)$-, wherein R^J is -H or $-CH_3$;

R^F and R^G independently are -H or $-CH_3$; and


R^A is $-CO_2H$ or $-CO_2R^B$.

34. The compound of claim 1 wherein the compound has the structure of Formula VI



Formula VI

wherein Ring A is a 5-membered heteroarene having one of the structures of:




wherein R^D is the -N(R^F)C(=O)CH(R^G)-CY substituent of Formula VI wherein CY is phenyl substituted with one R^H, and R^C is -H, -CH_3, CF_3 or -F.

R^A is -CO_2H or -CO_2R^B; and

R^F and R^G independently are -H or -CH_3; and

R^H independently are -H, halogen, -CH_3 or -CF_3.


35. The compound of claim 1 wherein the compound has the structure of Formula VII



Formula VII

wherein A^1 is =CH- or =N-;

Ring A is a 5 membered heteroarene having the structure of one of:



wherein R^D is the -N(R^F)C(=O)CH(R^G)-CY substituent of Formula VII wherein CY is phenyl substituted with one R^H; and R^C is -H, -CH_3, -CF_3 or -F;

R^A is -CO_2H or -CO_2R^B;


R^E and R^F independently are -H or C_1-C_4 alkyl;

R^G is -H or -CH_3;

R^H is -H, halogen, -CH_3 or -CF_3; and

Z is -C(R^L)$_2$, wherein one R^L is -H and the other R^L is -H or C_1-C_4 alkyl.


36. The compound of claim 1 wherein the compound has the structure of Formula VIII



Formula VIII

wherein A^1 is =CH- or =N-;

wherein Ring A is a 5 membered heteroarene having the structure of one of:



wherein R^D is the -N(R^F)C(=O)CH(R^G)-CY substituent of Formula VIII wherein CY is phenyl substituted with one R^H;

R^A is -CO_2H or -CO_2R^B;

W is -C(R^L)$_2$- or ;


R^E and R^F independently are -H or C_1-C_4 alkyl;

R^G is -H or $-CH_3$;

R^H is -H, halogen, $-CH_3$ or $-CF_3$; and

Z is $-C(R^L)_2$, wherein one R^L is -H and the other R^L is -H or C_1-C_4 alkyl.


37. The compound of claim 1 wherein the compound has the structure of Formula IX



Formula IX

wherein A^1 is =CH- or =N-;

wherein Ring A is a 5-membered heteroarene having the structure of one of:



wherein R^D is the $-N(R^F)C(=O)CH(R^G)$-CY substituent of Formula VII wherein CY is phenyl substituted with one R^H;

R^A is $-CO_2H$ or $-CO_2R^B$;

wherein W is $-C(R^L)_2$- or ;

R^E and R^F independently are -H or C_1-C_4 alkyl;

R^G is -H or $-CH_3$;

R^H is -H, halogen, $-CH_3$ or $-CF_3$; and

Z is $-C(R^L)_2$, wherein one R^L is -H and the other R^L is -H or C_1-C_4 alkyl.

38 The compound of claim 1 wherein the compound is 1-(4-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-cyclopropanecarboxylic acid, 2-(4-{4-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-indan-2-carboxylic acid, 2-(S)-(4-{4-[(R,S)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)phenyl acetic acid, 2-(R)-(4-{4-[(R,S)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)phenyl propanoic acid, (R)-2-{4-[3-Methyl-4-((S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzoylamino}-3-phenyl-propionic acid, (S)-2-{4-[3-Methyl-4-((S)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzoylamino}-3-phenyl-propionic acid, 2(R)-[[4-[3-methyl-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid, 2(S)-[[4-[3-methyl-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid, (R)-2-[[4-[2,5-dimethyl-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid, (R)-2-[[4-[1,5-dimethyl-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid, (R)-3-(4-bromophenyl)-2-[[4-[2,5-dimethyl-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, (R)-3-(4-bromophenyl)-2-[[4-[1,5-dimethyl-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, (R)-3-(4-chlorophenyl)-2-[[4-[2,5-dimethyl-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, (R)-3-(4-chlorophenyl)-2-[[4-[1,5-dimethyl-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, (R)-3-(3,4-difluorophenyl)-2-[[4-[2,5-dimethyl-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, (R)-3-(3,4-difluorophenyl)-2-[[4-[1,5-dimethyl-4-((R)-1-phenylethoxycarbonyl-amino)pyrazol-3-yl]benzoyl]amino]propanoic acid, (R)-2-[[4-[2,5-dimethyl-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-phenyl-propanoic acid, (R)-2-[[4-[1,5-dimethyl-4-((R)-1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]-3-phenyl-propanoic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-phenyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-(4-fluoro-phenyl)-propionic acid, (R)-3-(4-Chloro-phenyl)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-propionic acid, (R)-3-(4-Bromo-phenyl)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-(2-fluoro-phenyl)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-(4-trifluoromethyl-phenyl)-propionic acid, (R)-2-(4-{4-[(R)-

1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-(4-cyano-phenyl)-propionic acid, (R)-2-(4-{5-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-methyl-pyrazol-1-yl}-benzoylamino)-3-phenyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-(3,4-difluoro-phenyl)-propionic acid, (R)-3-(2-Chloro-phenyl)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-p-tolyl-propionic acid, (R)-2-{4-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzylamino}-3-phenyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzoylamino)-3-cyclopropyl-propionic acid, (RS)-2-{4-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-3-phenyl-propionic acid, , , (RS)-2-{4-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-3-phenyl-propionic acid, , (RS)-3-(4-Chloro-phenyl)-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonyloxy)-isoxazol-5-yl]-benzyloxy}-propionic acid, (RS)-3-Cyclopropyl-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzylamino)-3-phenyl-propionic acid, (R)-2-(4-{4-[(R)—1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzylamino)-3-(2-fluoro-phenyl)-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzylamino)-3-(4-trifluoromethyl-phenyl)-propionic acid, (R)-3-(2-Chloro-phenyl)-2-(4-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzylamino)-propionic acid, (R)-3-(2-Fluoro-phenyl)-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzylamino}-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzylamino)-3-cyclopropyl-propionic acid, (R)-2-{4-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzylamino}-3-(4-trifluoromethyl-phenyl)-propionic acid, (R)-3-Cyclopropyl-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzylamino}-propionic acid, (R)-3-(2-Chloro-phenyl)-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzylamino}-propionic acid, or (R)-3-(4-Chloro-phenyl)-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzylamino}-propionic acid,

39. The compound of claim 1 wherein the compound is (RS)-3-Cyclopropyl-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid , 2(R)-[[4-[3-methyl-4-((R)-1-phenylethoxycarbonylamino)isoxazol-5-yl]benzoyl]amino]-3-phenyl-propanoic acid, (R)-2-{4-[3-Methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzylamino}-3-

phenyl-propionic acid, (R)-2-(4-{4-[(R)-1-(2-Chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-benzylamino)-3-phenyl-propionic acid and (R)-3-Cyclopropyl-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzylamino}-propionic acid.

40. A compound of any one of claims 1-39 for preparation of mendicant for treating a LPA-dependent disease or condition.